DRUG INTERACTIONS IDHIFA

Effect Of IDHIFA On Other Drugs

OATP1B1, OATP1B3, And BCRP Substrates

IDHIFA is an OATP1B1, OATP1B3, and BCRP inhibitor. Coad ministration of IDHIFA increases the exposure of OATP1B1, OATP1B3, and BCRP substrates, which may increase the incidence and severity of adverse reactions of these substrates [see CLINICAL PHARMACOLOGY]. Decrease the dosage of OATP1B1, OATP1B3, and BCRP substrate(s) as recommended in the respective prescribing information, and as clinically indicated.

Certain P-glycoprotein (P-gp) Substrates

IDHIFA is a P-gp inhibitor. Coad ministration of IDHIFA increases the exposure of P-gp substrates, which may increase the incidence and severity of adverse reactions of these substrates [see CLINICAL PHARMACOLOGY]. For a P-gp substrate where small concentration changes may lead to serious adverse reactions, decrease the dose or modify the dosing frequency of such a P-gp substrate and monitor for adverse reactions as recommended in the respective prescribing information.

IDHIFA (ENASIDENIB)